8 results about "Virus type" patented technology

This invention relates to the field of biomedical technology, providing a rabbit hemorrhagic disease virus (RHDV) type 2 fusion antigen protein and its applications. The fusion antigen protein comprises the RHDV2 VP60 protein sequence and an immunomodulatory CRM197 protein functional fragment, fused together via a linker peptide, and expressed and purified in an insect cell expression system. This invention improves the immunogenicity of the antigen protein by fusing the major capsid protein VP60 of RHDV2 with the immunomodulatory fragment of CRM197. Rabbit immunization experiments verified that the fusion antigen protein can induce high-titer specific antibodies, with serum antibody titers reaching 1:12800 and above, demonstrating good immunization effects. The fusion antigen protein of this invention can be used to prepare a vaccine for the prevention of RHDV2 infection, providing a new technical solution for the prevention and control of RHDV2 disease.

The application discloses a broad-spectrum neutralizing pig-derived monoclonal antibody of type A foot-and-mouth disease virus (FMDV) and application thereof. The antibody PAF56 has an amino acid sequence of a heavy chain variable region as shown in SEQ ID No. 12, a heavy chain CDR1 sequence of GFGFSNTY, a heavy chain CDR2 sequence of VFTGGGAT, and a heavy chain CDR3 sequence of VSNRDGFGGVGNV. The antibody PAF56 has an amino acid sequence of a light chain variable region as shown in SEQ ID No. 13, a light chain CDR1 sequence of SGSVTSLNY, a light chain CDR2 sequence of RTN, and a light chain CDR3 sequence of ALYKGSGTDTNI. The antibody PAF56 can simultaneously neutralize an AF72 strain of an A22 lineage and A / WH / CHA / 09 and A / GDMM / 2013 epidemic strains of a domestic SEA97 lineage, and has broad-spectrum neutralization activity of type A FMDV. The antibody PAF56 recognizes an antigen site 2 of a VP2 B-C loop, and a key amino acid is VP2 D72; the recognized site is highly conserved in type A FMDV. The application first obtains a broad-spectrum neutralizing antibody of type A specific FMDV from a natural host and identifies a key antigen site recognized by the antibody, thereby providing a powerful tool for antigen structure analysis of FMDV and establishment of a serological detection method.

The present disclosure relates to a recombinant protein comprising a food and mouth disease virus (FMDV) virus like particle (VLP) and a fragment crystallizable region (Fc) of a swine-derived immunoglobulin linked to the surface of the VLP, and a vaccine composition comprising the recombinant protein. The recombinant protein of the present disclosure may form a self-assembling structure including a virus-like particle using a protein derived from a capsid protein of FMDV, which is an antigenic protein, and a swine Fc protein located on the surface of the virus-like particle, and by using a vaccine composition including the recombinant protein, a specific antibody against FMDV may be effectively produced.

The invention relates to the technical field of vaccine preparation, in particular to a bivalent subunit vaccine based on rabbit hemorrhagic disease virus type 2 VLPs and pasteurella multocida OMV as well as a preparation method and application of the bivalent subunit vaccine based on the rabbit hemorrhagic disease virus type 2 VLPs and the pasteurella multocida OMV. The vaccine is obtained by combining type 2 rabbit hemorrhagic disease virus VLPs and pasteurella multocida OMV; the mass ratio of the type 2 rabbit hemorrhagic disease virus VLPs to the pasteurella multocida OMV is 1: 1 or 1: 2. The invention aims to construct a novel bivalent vaccine capable of preventing RHDV2 and Pm infection at the same time. Establishing a preparation process of VLPs of RHDV2 and OMV of Pm, and efficiently combining the VLPs and the OMV to form a bivalent subunit vaccine; the optimal immune dose and the scientific immune procedure are defined by performing immune test and challenge protection effect evaluation on the domestic rabbits. The research aims at providing a scientific basis for developing the RHDV2 and rabbit Pm bigeminy subunit vaccine, has industrial development potential and has important significance on high-quality development of the special rabbit industry.

The present invention aims to provide mRNA and its application. Based on the gene sequence of the VP60 protein receptor binding region of rabbit hemorrhagic disease virus type 1 and type 2 strains isolated and prevalent in China, candidate mRNA expressing the VP60 target antigen of RHDV1 and RHDV2 was constructed using messenger RNA (mRNA) technology. This mRNA was then used to prepare a third-generation rabbit plague vaccine, which carries the sequence information of the antigenic protein and can be effectively translated into the antigenic protein in the cytoplasm, stimulating both cellular and humoral immune responses. Experiments using this vaccine to immunize rabbits have shown that it can induce high levels of antibodies against RHDV1 and RHDV2, and provides good protection against prevalent isolates of RHDV1 and RHDV2. The vaccine exhibits significant advantages in safety and immune efficacy.

The present disclosure provides isolated peptides derived from human T-lymphotropic virus type 1 (HTLV-1), peptide-based molecules (e.g., peptide-MHC (pMHC) complexes), polynucleotides and vectors encoding the peptides or peptide-based molecules, pharmaceutical compositions (e.g., vaccine compositions), and their use for treating, preventing, and / or reducing the likelihood of HTLV-1 infection and / or HTLV-1-induced disease. The present disclosure also provides binding moieties that bind to the peptides or peptide-based molecules disclosed herein, and their use for treating, preventing, and / or reducing the likelihood of HTLV-1 infection and / or HTLV-1-induced disease. The present disclosure also provides methods and systems for identifying immunogenic virus-derived peptides.

Described is a vaccine against porcine reproductive and respiratory syndrome (PRRS) caused by PRRS virus type 1 (PRRSV-1), which comprises an apathogenic live strain of PRRS virus type 2 (PRRSV-2) and a pharmaceutically acceptable vehicle, adjuvant and / or excipient. The vaccine prevents the disease caused by PRRSV-1.

To provide compositions and methods for detecting a viral pathogen in a sample.SOLUTION: The present disclosure relates to amplification primers, hybridization assay probes, compositions containing such primers and probes, and related reagents, kits, and methods that can be used to analyze samples for the presence of influenza A virus, influenza B virus, respiratory syncytial virus type A, and / or respiratory syncytial virus type B target nucleic acids.SELECTED DRAWING: None